Keryx Biopharmaceuticals (KERX) Shares are Up 4.58%

Keryx Biopharmaceuticals (KERX) has been under a strong bear grip, hence the stock is down -37.78% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.27% in the past 1 week. The stock has risen by 4.58% in the past week indicating that the buyers are active at lower levels, but the stock is down -37.91% in the past 4 weeks.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 0.18% and the fifty day Moving Average is 22.74%. Keryx Biopharmaceuticals Inc. has dropped 22.01% during the last three month period . Year-to-Date the stock performance stands at -9.5%.

Keryx Biopharmaceuticals (KERX) : The highest level Keryx Biopharmaceuticals (KERX) is projected to reach is $9 for the short term and the lowest estimate is at $4. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $7.2 and the possibility the share price can swing is $2.05.


Keryx Biopharmaceuticals (NASDAQ:KERX): On Fridays trading session , Opening price of the stock was $4.63 with an intraday high of $4.8. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.53. However, the stock managed to close at $4.57, a loss of 1.30% for the day. On the previous day, the stock had closed at $4.63. The total traded volume of the day was 1,270,980 shares.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.